IP analysis: The patents court has held that Takeda’s Vedolizumab product (Entyvio) is an antibody within the claims of Roche’s European patent titled ‘Glycosylated Antibodies,’ but found that the patent ought to be revoked because all the relevant claims are invalid due to a lack of novelty, a lack of technical contribution and insufficiency.
Welcome to the weekly Energy highlights from the Lexis®PSL Environment team for the week ending 5 May 2016. This week’s edition of the Energy highlights includes electricity and gas regulation, nuclear safety, and Ofgem decisions, guidance and consultations.
Read the latest 2 News articles on ASN
Speed up all aspects of your legal work with tools that help you to work faster and smarter. Win cases, close deals and grow your business–all whilst saving time and reducing risk.
**Trials are provided to all LexisNexis content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisNexis services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
"Although cost was an important factor, our relationship with LexisNexis, their responsiveness, flexibility, and the integration available with other products were key factors."
Access all documents on ASN
0330 161 1234